NATCO Pharma Limited (BOM:524816)
888.75
+5.50 (0.62%)
At close: Jun 19, 2026
NATCO Pharma Revenue
In the fiscal year ending March 31, 2026, NATCO Pharma had annual revenue of 40.78B INR, down -7.98%. NATCO Pharma had revenue of 7.39B in the quarter ending March 31, 2026, a decrease of -39.59%.
Revenue
40.78B
Revenue Growth
-7.98%
P/S Ratio
3.88
Revenue / Employee
9.71M
Employees
4,199
Market Cap
158.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 40.78B | -3.54B | -7.98% |
| Mar 31, 2025 | 44.32B | 4.30B | 10.74% |
| Mar 31, 2024 | 40.02B | 12.94B | 47.76% |
| Mar 31, 2023 | 27.09B | 7.62B | 39.17% |
| Mar 31, 2022 | 19.46B | -1.10B | -5.35% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 82.80B |
| Granules India | 53.66B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 38.22B |
| Viyash Scientific | 34.20B |
| AstraZeneca Pharma India | 22.76B |
| Caplin Point Laboratories | 21.87B |
| Sanofi India | 17.74B |
NATCO Pharma News
- 4 days ago - Pharma sector stocks rises today, June 18: Wockhardt up 2.86%, Natco Pharma gains 2.38%, Panacea Biotech rises 2.01% - Business Upturn
- 10 days ago - Pharma sector stocks rise today, June 12: Panacea Biotech gains 2.50%, Wockhardt rises 2.24%, Natco Pharma up 1.36% - Business Upturn
- 17 days ago - Pharma sector stocks today, June 5: Panacea Biotech up 6.14%, Wockhardt falls 6.49%, Natco Pharma down 1.79% - Business Upturn
- 18 days ago - Pharma sector stocks today, June 4: Panacea Biotech up 7.24%, Wockhardt gains 3.09%, Natco Pharma falls 1.63% - Business Upturn
- 19 days ago - Lupin And Natco Receive FDA Approval For Eribulin Mesylate Injection - Nasdaq
- 19 days ago - Lupin, Natco Receive FDA Approval For Eribulin Mesylate Injection - Nasdaq
- 19 days ago - Natco Pharma and Lupin secure U.S. FDA approval for Eribulin Mesylate Injection - Business Upturn
- 19 days ago - Pharma sector stocks today, June 3: Natco Pharma falls 2.57%, Zydus Lifesciences falls 1.26%, Alembic Pharma down 1.06% - Business Upturn